BIIB Q2 2021 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q2 2021 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$2.8B-24.6% YoY

Gross Profit

$2.3B83.4% margin

Operating Income

$471M17.0% margin

Net Income

$449M16.2% margin

EPS (Diluted)

$2.99

QoQ Revenue Growth

+3.0%

Cash Flow

Operating Cash Flow

$1.2B

Free Cash Flow

$1.2B

Stock-Based Comp.

$54M

Balance Sheet

Total Assets

$24.5B

Total Liabilities

$13.3B

Stockholders' Equity

$10.8B

Cash & Equivalents

$1.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.8B	$3.7B	-24.6%
Gross Profit	$2.3B	$3.3B	-29.2%
Operating Income	$471M	$2.0B	-76.2%
Net Income	$449M	$1.5B	-70.9%

Revenue Segments

MS Product Revenues

$1.5B43%

Fumarate

$579M16%

TYSABRI product

$524M15%

SPINRAZA

$500M14%

Interferon

$400M11%

Geographic Segments

Non-US

$1.3B56%

UNITED STATES

$977M44%